TGF-β inhibitorC
US10822337B2 · kind B2 · utility
4Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2016 |
| Grant date | Nov 3, 2020 |
| Priority date | — |
| Expiry date | Mar 30, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.